Nissay Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.05M | Buy |
77,952
+1,990
| +3% | +$167K | 0.03% | 312 |
|
|
2026
Q1 | $6.08M | Buy |
75,962
+189
| +0.2% | +$15.6K | 0.03% | 289 |
|
|
2025
Q4 | $6.46M | Buy |
75,773
+923
| +1% | +$75.7K | 0.03% | 279 |
|
|
2025
Q3 | $5.82M | Buy |
74,850
+749
| +1% | +$58.5K | 0.03% | 290 |
|
|
2025
Q2 | $5.8M | Sell |
74,101
-121
| -0.2% | -$9.02K | 0.03% | 298 |
|
|
2025
Q1 | $5.38M | Sell |
74,222
-614
| -0.8% | -$43.9K | 0.04% | 305 |
|
|
2024
Q4 | $5.66M | Sell |
74,836
-1,650
| -2% | -$115K | 0.03% | 295 |
|
|
2024
Q3 | $5.05M | Buy |
76,486
+2,220
| +3% | +$161K | 0.03% | 313 |
|
|
2024
Q2 | $6.86M | Sell |
74,266
-1,083
| -1% | -$95.9K | 0.05% | 249 |
|
|
2024
Q1 | $7.2M | Buy |
75,349
+639
| +0.9% | +$53.7K | 0.05% | 233 |
|
|
2023
Q4 | $5.7M | Buy |
74,710
+2,602
| +4% | +$181K | 0.05% | 232 |
|
|
2023
Q3 | $5M | Buy |
72,108
+2,467
| +4% | +$198K | 0.04% | 236 |
|
|
2023
Q2 | $6.57M | Sell |
69,641
-2,478
| -3% | -$215K | 0.06% | 199 |
|
|
2023
Q1 | $5.97M | Sell |
72,119
-2,434
| -3% | -$191K | 0.05% | 202 |
|
|
2022
Q4 | $5.56M | Sell |
74,553
-2,171
| -3% | -$167K | 0.05% | 216 |
|
|
2022
Q3 | $6.34M | Buy |
76,724
+2,246
| +3% | +$216K | 0.07% | 177 |
|
|
2022
Q2 | $7.08M | Sell |
74,478
-2,730
| -4% | -$283K | 0.07% | 162 |
|
|
2022
Q1 | $9.09M | Buy |
77,208
+1,633
| +2% | +$183K | 0.08% | 150 |
|
|
2021
Q4 | $9.79M | Buy |
75,575
+5,208
| +7% | +$607K | 0.08% | 158 |
|
|
2021
Q3 | $7.97M | Buy |
70,367
+2,032
| +3% | +$232K | 0.07% | 167 |
|
|
2021
Q2 | $7.08M | Buy |
68,335
+1,403
| +2% | +$132K | 0.06% | 185 |
|
|
2021
Q1 | $5.6M | Sell |
66,932
-1,347
| -2% | -$114K | 0.06% | 199 |
|
|
2020
Q4 | $6.23M | Sell |
68,279
-2,430
| -3% | -$202K | 0.09% | 176 |
|
|
2020
Q3 | $5.64M | Sell |
70,709
-11,759
| -14% | -$918K | 0.1% | 174 |
|
|
2020
Q2 | $5.7M | Sell |
82,468
-1,394
| -2% | -$99.1K | 0.11% | 181 |
|
|
2020
Q1 | $5.27M | Buy |
83,862
+4,839
| +6% | +$349K | 0.13% | 159 |
|
|
2019
Q4 | $6.14M | Sell |
79,023
-2,949
| -4% | -$230K | 0.14% | 174 |
|
|
2019
Q3 | $6.01M | Sell |
81,972
-2,778
| -3% | -$195K | 0.15% | 165 |
|
|
2019
Q2 | $5.22M | Sell |
84,750
-2,580
| -3% | -$156K | 0.13% | 174 |
|
|
2019
Q1 | $5.57M | Sell |
87,330
-5,052
| -5% | -$288K | 0.15% | 165 |
|
|
2018
Q4 | $4.72M | Buy |
92,382
+3,342
| +4% | +$169K | 0.14% | 180 |
|
|
2018
Q3 | $5.17M | Buy |
89,040
+1,773
| +2% | +$86.7K | 0.14% | 180 |
|
|
2018
Q2 | $4.23M | Sell |
87,267
-4,440
| -5% | -$207K | 0.12% | 204 |
|
|
2018
Q1 | $4.26M | Sell |
91,707
-4,746
| -5% | -$206K | 0.13% | 200 |
|
|
2017
Q4 | $3.62M | Buy |
+96,453
| New | +$3.54M | 0.11% | 240 |
|
Other funds holding EW
Nissay Asset Management's EW Position: Q2 2026 in Review
Nissay Asset Management increased its Edwards Lifesciences (EW) stake by 2.6% in Q2 2026, buying an estimated $167K and bringing the position to 77,952 shares worth $7.05M. The position accounts for 0.03% of the portfolio, ranked #312.
Nissay Asset Management first reported a position in EW in Q4 2017 and has held it in 35 quarters since. The position peaked at $9.79M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Nissay Asset Management held 77,952 shares of Edwards Lifesciences worth $7.05M as of Q2 2026.
- Nissay Asset Management bought 1,990 Edwards Lifesciences shares in Q2 2026, an estimated $167K.
- Edwards Lifesciences made up 0.03% of Nissay Asset Management's portfolio in Q2 2026, its #312 holding.
- Nissay Asset Management first reported a position in Edwards Lifesciences in Q4 2017 and has held it in 35 quarters since.
- Nissay Asset Management's Edwards Lifesciences position peaked at $9.79M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Nissay Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.